JBM  Vol.7 No.5 , May 2019
Treatment of Irritable Bowel Syndrome with a Combination of Curcumin, Green Tea and Selenomethionine Has a Positive Effect on Satisfaction with Bowel Habits
Abstract: Background: Irritable bowel syndrome (IBS) is a common disorder impairing patient’s quality of life. Currently, there is no effective treatment for this syndrome. Coltect is a dietary supplement containing curcumin, green tea and selenomethionine. Aim: To investigate the effects of Coltect on IBS symptoms. Methods: A randomized, prospective, placebo-controlled, double blinded, crossover study. The study population included patients diagnosed with IBS by Rome criteria. Subjects were randomized to receive either Coltect or placebo for 4 weeks, and then received the opposite treatment for 4 weeks following a washout period of 2 weeks. The placebo was a pill, identical in color and size to the Coltect pill, with no active ingredients. Patients completed IBS health-related quality of life, severity score and IBS symptom questionnaires before and after each treatment period. Results: The study included 22 patients, ages 22 – 77 years. Coltect had a positive effect on patients’ satisfaction with their bowel habits (as measured on a scale from 0—Very satisfied to 100—Very unsatisfied). Average score was 70.4 ± 33.1 before and 61.8 ± 29.3 after Coltect treatment (p = 0.037). Other parameters, including abdominal pain, bloating, and effects of IBS on daily activity, symptoms, IBS-related quality of life and general health quality of life were unchanged. Conclusion: Coltect seems to have a positive effect on satisfaction with bowel habits.
Cite this paper: Lior, O. , Sklerovsy-Benjaminov, F. , Lish, I. , Konokoff, F. and Naftali, T. (2019) Treatment of Irritable Bowel Syndrome with a Combination of Curcumin, Green Tea and Selenomethionine Has a Positive Effect on Satisfaction with Bowel Habits. Journal of Biosciences and Medicines, 7, 170-179. doi: 10.4236/jbm.2019.75018.

[1]   Drossman, D.A., Camilleri, M., Mayer, E.A. and Whitehead, W.E. (2002) AGA Technical Review on Irritable Bowel Syndrome. Gastroenterology, 123, 2108-2131.

[2]   Peery, A.F., Dellon, E.S., Lund, J., et al. (2012) Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology, 143, 1179-1187.

[3]   Mearin, F., Lacy, B.E., Chang, L., Longstreth, G.F., Thompson, W.G., Chey, W.D., et al. (2006) Functional Bowel Disorders. Gastroenterology, 130, 148-1491.

[4]   Ford, A.C., Moayyedi, P., Lacy, B.E., et al. (2014) American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology, 109, S2-S26.

[5]   Drossman, D.A., Chey, W.D., Johanson, J.F., et al. (2009) Clinical Trial: Lubiprostone in Patients with Constipation-Associated Irritable Bowel Syndrome—Results of Two Randomized, Placebo-Controlled Studies. Alimentary Pharmacology & Therapeutics, 29, 329-341.

[6]   Pimentel, M., Lembo, A., Chey, W.D., et al. (2011) Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. The New England Journal of Medicine, 364, 22-32.

[7]   Lembo, A.J., Lacy, B.E., Zuckerman, M.J., et al. (2016) Eluxadoline for Irritable Bowel Syndrome with Diarrhea. The New England Journal of Medicine, 374, 242-253.

[8]   Tornblom, H., Lindberg, G., Nyberg, B. and Veress, B. (2002) Full-Thickness Biopsy of the Jejunum Reveals Inflammation and Enteric Neuropathy in Irritable Bowel Syndrome. Gastroenterology, 123, 1972-1979.

[9]   Chadwick, V.S., Chen, W., Shu, D., et al. (2002) Activation of the Mucosal Immune System in Irritable Bowel Syndrome. Gastroenterology, 122, 1778-1783.

[10]   Guilarte, M., Santos, J., de Torres, I., et al. (2007) Diarrhoea-Predominant IBS Patients Show Mast Cell Activation and Hyperplasia in the Jejunum. Gut, 56, 203-209.

[11]   Dinan, T.G., Quigley, E.M., Ahmed, S.M., et al. (2006) Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker? Gastroenterology, 130, 304-311.

[12]   Bueno, L. (2008) Protease Activated Receptor 2: A New Target for IBS Treatment. European Review for Medical and Pharmacological Sciences, 12, 95-102.

[13]   Gecse, K., Róka, R., Ferrier, L., et al. (2008) Increased Faecal Serine Protease Activity in Diarrhoeic IBS Patients: A Colonic Lumenal Factor Impairing Colonic Permeability and Sensitivity. Gut, 57, 591-599.

[14]   Liebregts, T., Adam, B., Bredack, C., et al. (2007) Immune Activation in Patients with Irritable Bowel Syndrome. Gastroenterology, 132, 913-920.

[15]   Larmonier, C.B., Midura-Kiela, M.T., Ramalingam, R., et al. (2011) Modulation of Neutrophil Motility by Curcumin: Implications for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 17, 503-515.

[16]   Epstein, J., Docena, G., MacDonald, T.T. and Sanderson, I.R. (2010) Curcumin Suppresses p38 Mitogen-Activated Protein Kinase Activation, reduces IL-1β and Matrix Metalloproteinase-3 and Enhances IL-10 in the Mucosa of Children and Adults with Inflammatory Bowel Disease. British Journal of Nutrition, 103, 824-832.

[17]   Jobin, C., Bradham, C.A., Russo, M.P., et al. (1999) Curcumin Blocks Cytokine Mediated NF-Kappa B Activation and Proinflammatory Gene Expression by Inhibiting Inhibitory Factor I-Kappa B Kinase Activity. The Journal of Immunology, 163, 3474-3483.

[18]   Gupta, S.C., Patchva, S. and Aggarwal, B.B. (2013) Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. The AAPS Journal, 15, 195-218.

[19]   Mazzon, E., Muià, C., Paola, R.D., Genovese, T., Menegazzi, M., De Sarro, A., Suzuki, H. and Cuzzocrea, S. (2005) Green Tea Polyphenol Extract Attenuates Colon Injury Induced by Experimental Colitis. Free Radical Research, 39, 1017-1025.

[20]   Sunde, R.A. (2010) Selenium. In: Coates, P.M., Betz, J.M., Blackman, M.R., et al., Eds., Encyclopedia of Dietary Supplements, 2nd Edition, Informa Healthcare, London and New York, 711-718.

[21]   Thompson, P.A., Ashbeck, E.L., Roe, D.J., Fales, L., Buckmeier, J., Wang, F., Bhattacharyya, A., Hsu, C.H., Chow, H.H., Ahnen, D.J., Boland, C.R., Heigh, R.I., Fay, D.E., Hamilton, S.R., Jacobs, E.T., Martinez, M.E. and Alberts, D.S. (2016) Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. Journal of the National Cancer Institute, 108.

[22]   Shapira, S., Lesho, A., Katz, D., et al. (2017) Of Mice and Men: A Novel Dietary Supplement for a Treatment of Ulcerative Colitis. Therapeutic Advances in Gastroenterology, 11.

[23]   Altman, D.G. and Bland, J.M. (1999) How to Randomise. British Medical Journal, 319, 703-704.

[24]   Drossman, D.A., Patrick, D.L., Whitehead, W.E., Toner, B.B., Diamant, N.E., Hu, Y., Jia, H. and Bangdiwala, S.I. (2000) Further Validation of the IBS-QOL: A Disease-Specific Quality-of-Life Questionnaire. American Journal of Gastroenterology, 95, 1000-1007.

[25]   Drossman, D., Morris, C.B., Hu, Y., Toner, B.B., Diamant, N., Whitehead, W.E., Dalton, C.B., Leserman, J., Patrick, D.L. and Bangdiwala, S.I. (2007) Characterization of Health Related Quality of Life (HRQOL) for Patients With Functional Bowel Disorder (FBD) and Its Response to Treatment. American Journal of Gastroenterology, 102, 1442-1453.